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Introduction:Although many reports have shown the safety and 
efficacy of stereotactic body radiotherapy (SBRT) for T1N0M0 non–
small-cell lung cancer (NSCLC), it is rather difficult to treat T2N0M0 
NSCLC, especially T2b (>5 cm) tumor, with SBRT. Our hypothesis 
was that particle therapy might be superior to SBRT in T2 patients. 
We evaluated the clinical outcome of particle therapy for T2a/bN0M0 
NSCLC staged according to the 7th edition of the International Union 
Against Cancer (UICC) tumor, node, metastasis classification.
Methods:From April 2003 to December 2009, 70 histologically con-
firmed patients were treated with proton (n = 43) or carbon-ion (n = 
27) therapy according to institutional protocols. Forty-seven patients 
had a T2a tumor and 23 had a T2b tumor. The total dose and fraction 
(fr) number were 60 (Gray equivalent) GyE/10 fr in 20 patients, 52.8 
GyE/4 fr in 16, 66 GyE/10 fr in 16, 80 GyE/20 fr in 14, and other in 
four patients, respectively. Toxicities were scored according to the 
Common Terminology Criteria for Adverse Events, Version 4.0.
Results:The median follow-up period for living patients was 51 
months (range, 24–103). For all 70 patients, the 4-year overall sur-
vival, local control, and progression-free survival rates were 58% 
(T2a, 53%; T2b, 67%), 75% (T2a, 70%; T2b, 84%), and 46% (T2a, 
43%; T2b, 52%), respectively, with no significant differences between 
the two groups. The 4-year regional recurrence rate was 17%. Grade 
3 pulmonary toxicity was observed in only two patients.
Conclusion:Particle therapy is well tolerated and effective for T2a/
bN0M0 NSCLC. To further improve treatment outcome, adjuvant 
chemotherapy seems a reasonable option, whenever possible.
Key Words: Proton therapy, Carbon-ion therapy, Non–small-cell 
lung cancer, T2a/2b, 7th edition International Union Against Cancer, 
tumor, node, metastasis classification.
(J Thorac Oncol. 2013;8: 726-735)
Tumor size is an important factor influencing the local control probability by radiation therapy. Generally, as the 
tumor becomes larger, the clonogenic cell number, hypoxic 
fraction, and quiescent cell fraction increase,1,2 leading to ele-
vated resistance to photon radiotherapy. However, biological 
and clinical evidences suggest that particle therapy may be 
useful for relatively large but localized tumors, such as hepato-
cellular carcinoma larger than 5 cm.3,4 Therefore, stage I non–
small-cell lung cancer (NSCLC) larger than 3 cm in diameter 
(T2) may also be a good indication of particle therapy.
The 7th edition of the tumor node metastasis (TNM) 
staging system for NSCLC proposed by the International 
Association for the Study of Lung Cancer and approved by 
the International Union Against Cancer and the American 
Joint Committee on Cancer has been in use since 2010.5 
The changes between the 6th and 7th editions were the new 
cutoff sizes for primary tumors, subdivisions of the T and M 
categories, and reclassification of malignant pleural effusions 
and separate tumor nodules. As for the T category, T1 tumors 
were subdivided into T1a (≤ 2 cm) and T1b (> 2 to ≤ 3 cm), 
T2 tumors into T2a (> 3 to ≤ 5 cm) and T2b (>5 to ≤7 cm), 
and T2 tumors more than 7 cm were reclassified as T3.6,7 In 
addition, T2bN0M0 cases were classified from stage IB to 
stage IIA. The proposed changes to the 7th edition of the 
TNM classification of NSCLC emphasize the prognostic 
relevance of tumor size much more than in previous editions. 
Tumor size correlated with the prognosis of patients clinically 
staged as N0. In recent years, stereotactic body radiotherapy 
(SBRT) has been gaining popularity worldwide as a new 
treatment modality for stage I NSCLC.8,9 Many reports have 
shown that SBRT is safe and effective for T1N0M0 NSCLC. 
However, it is difficult to treat T2N0M0 NSCLC, especially 
T2b (>5 cm), with SBRT.10,11 Compared with conventional 
radiation, SBRT produces superior dose distribution at the 
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target while simultaneously reducing the irradiated normal 
tissue volume. However, with an increase in tumor size, local 
control becomes poorer and the risk of high-grade radiation 
pneumonitis (RP) increases. Previous reports have shown a 
correlation between severe RP and dose-volume parameters 
such as the mean lung dose.12 Obviously, with the increase in 
tumor size, the dose to normal lung increases and the risk of 
RP becomes high. Therefore, particle therapy is considered to 
be indicated for larger lesions.
We previously reported the results of proton therapy 
(PT) and carbon-ion therapy (CIT) for 80 stage I NSCLC 
patients, including 38 T2 cases, staged according to the 6th 
edition of TNM classification, between April 2003 and April 
2007 at Hyogo Ion Beam Medical Center (Tatsuno, Japan).13 
In our previous study, particle therapy was safe and effective 
for both T1N0M0 and T2N0M0 NSCLC. Particle therapy can 
preserve the homogeneity to a target and lower the low-dose 
region in the lung and the mean lung dose compared with 
SBRT using photons.14 Moreover, particle therapy, especially 
CIT, has high relative biological effectiveness and an advan-
tage against hypoxic tumor cells in terms of a lower oxygen 
enhancement ratio. Therefore, it was hypothesized that par-
ticle therapy might be superior to SBRT in T2 patients. In 
the present study, we restaged the patients with early NSCLC 
based on the 7th edition of the TNM classification and ana-
lyzed the clinical outcome of particle therapy for T2a and 
T2bN0M0 NSCLC.
MATERIALS AND METHODS
Study Design and Patient Eligibility 
and Characteristics
Particle therapy was performed in clinical studies based 
on protocols determined by the particle therapy committee of 
Hyogo prefecture and approved by the Institutional Review 
Board. Early clinical results of the study were reported previ-
ously.13 The eligibility criteria for the clinical studies were as 
follows: (1) histologically confirmed primary NSCLC staged 
as T1N0M0 or T2N0M0 by the 6th UICC TNM classification 
using computed tomography (CT) scans, bone scans, brain 
magnetic resonance imaging, and 18-fluoro-deoxyglucose-pos-
itron emission tomography; (2) medical inoperability or refusal 
of surgical resection; (3) World Health Organization perfor-
mance status of 2 or less; (4) no history of lung cancer; (5) no 
previous chest radiotherapy or chemotherapy; and (6) written 
informed consent. Of the 139 patients treated between April 
2003 and December 2009, 70 patients, restaged as T2aN0M0 
or T2bN0M0 according to the 7th UICC classification, were the 
subject of this study. Forty-seven patients had a T2a tumor and 
23 had a T2b tumor. No tumors lesser or equal to 3 cm, in their 
greatest dimension, invaded the main bronchus (< 2 cm from 
the carina) or the visceral pleura, and no tumors were associated 
with atelectasis or obstructive pneumonitis extending to the hilar 
region. Therefore, all tumors had a diameter of more than 3 cm. 
Fifty-one patients were men and 19 were women. Patient age 
ranged from 57 to 92 years (median, 75 years). Forty patients 
were medically inoperable and 30 refused surgery. Patient and 
tumor characteristics are summarized in Table 1.
Treatment Protocols and Treatment Systems
The treatment protocols have been evaluated by the 
committee and subjected to minor modifications whenever 
necessary. Our treatment protocols, used from April 2003 
to 2007, were described in detail previously.13 In brief, three 
treatment protocols were prepared by referring to those of 
other facilities. The first PT protocol, 80 Gray equivalent 
(GyE) delivered in 20 fractions, was set on the basis of earlier 
experiences at the National Cancer Center East (Kashiwa, 
Japan). After evaluating acute and medium-term toxicity in 
15 patients, the second PT protocol, 60 GyE delivered in 10 
fractions based on the protocol of Proton Medical Research 
Center (Tsukuba, Japan), was started to shorten the overall 
treatment time. The CIT protocol was 52.8 GyE delivered in 
four fractions, based on the National Institute of Radiological 
Sciences protocol (Chiba, Japan). After this period, the 
following new protocols were used. In May 2007, a revision 
of one of the PT protocols (from 60 to 66 GyE in 10 fractions) 
was started after 37 patients, with stage I NSCLC, had accrued 
at the time of a minor update to the system (improvement in the 
respiratory gating system) after we evaluated the toxicity and 
efficacy of this protocol (at least 35 patients) in our previous 
study.13 In January 2008, a new CIT protocol, 66 GyE in 10 
fractions was started on the basis of our previous results.13 The 
previous CIT protocol, 52.8 GyE delivered in four fractions, 
was stopped in January 2009, taking into consideration late 
toxicities of hypofractionation. As an exception, three patients 
were treated with other fractionation schedules, considering the 
proximity to risk organs in this study. The dose-fractionation 
schedules used are shown in Table 2. All radiation doses were 
delivered to the center of the tumor. All irradiation was given 
once a day, 5 days a week. The policy for selecting beam type 
was based partly on the availability of the particle beams; 
between April 2004 and March 2005, only PT was available. 
In April 2005, CIT became available, and thereafter, treatment 
plans for both PT and CIT were made for every patient. Then, 
the dose-volume histograms were compared, and a more 
suitable modality (PT or CIT) was determined and was then 
actually used for each patient. Chemotherapy was not included 
in these protocols. Our treatment systems at Hyogo Ion Beam 
Medical Center have been described in detail previously.13,15 A 
TABLE 1.  Patient and Tumor Characteristics
Characteristics T2aN0M0 T2bN0M0 Total
No. of patients 47 23 70
Age (yr)a 75 (57–87) 76 (60–92) 75 (57–92)
Sex male / female 31 / 16 20 / 3 51 / 19
PS 0 / 1 / 2 25 / 16 / 6 8 / 10 / 5 33 / 26 / 11
Refusal / medical inoperability 23 / 24 7 / 16 30 / 40
Pulmonary comorbidity 14 10 24
Longest tumor diameter (mm)a 38 (31–48) 56 (51–70) 41 (31–70)
Histology AD / SQ / other 27 / 14 / 6 12 / 7 / 4 39 / 21 / 10
Smoking history (+ / −) 33 / 14 19 / 4 52 / 18
Peripheral / central 42 / 5 18 / 5 60 / 10
a Median (range).
PS, performance status; AD, adenocarcinoma; SQ, squamous cell carcinoma.
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respiratory gating irradiation system developed at the National 
Institute of Radiological Sciences in Chiba16 was used until 
April 2007, and AZ-733 (Anzai Medical Co. Ltd., Tokyo, 
Japan) was used from May 2007. The radiation treatment plans 
were performed using a CT-based three-dimensional treatment 
planning system (FOCUS-M; CMS, St. Louis and Mitsubishi 
Electric Corporation, Tokyo, Japan] until April 2008 and Xio-M 
[CMS, St. Louis, USA and Mitsubishi Electric Corporation, 
Tokyo, Japan] from May 2008). A collision detection system 
(Mitsubishi Electric Corporation, Tokyo, Japan) was improved 
to shorten the air gap from February 2010. All radiation doses 
were prescribed to the center of the tumor (isocenter). Initially, 
the clinical target volume was covered with at least 95% of 
the isocenter dose, and the goal of planning target volume 
coverage was also 95%. From May 2007, the planning target 
volume coverage was set as at least 95%, similar to photon 
SBRT studies. Dose-volume analysis results are summarized 
in Table 2.
Follow-Up Examinations and Statistical Analysis
After particle therapy, the patients were followed with 
physical examinations, diagnostic imaging, and blood tests, 
including tumor marker examinations. Follow-up studies and 
evaluation of tumor recurrence have been described in detail 
previously.13 Toxicities were initially scored with the Common 
Terminology Criteria for Adverse Events, version 3.0, but 
were reclassified according to version 4.0. Grade 2 RP was 
defined as symptomatic, requiring medical management, but 
not interfering with activities of daily living. Grade 3 RP was 
defined as severely symptomatic, requiring oxygen adminis-
tration and interfering with activities of daily living. Statistical 
analyses were carried out with SPSS 11.0J (SPSS Japan Inc., 
Tokyo, Japan) and StatView version 5 (SAS Institute Inc., 
Cary, NC). The overall survival, local control, progression-
free survival, and regional recurrence rates were calculated 
using the Kaplan–Meier method. Differences between pairs of 
Kaplan–Meier curves were examined by the log-rank test. A 
p value less than 0.05 was considered statistically significant.
RESULTS
Dose Distribution
Figure 1 shows four examples of particle therapy 
planning for T2a NSCLC. Doses of the skin and ribs were 
relatively high, especially when treated with one portal, 
because of relatively high entry doses from the spread-out 
Bragg peaks (SOBP).
Survival and Local Control
All patients were observed for a minimum of 2 years 
or until death. The median duration of follow-up was 51 
months (range, 24–103) for living patients and 44 months 
(range, 4–103) for all patients. For all 70 patients, the 4-year 
overall survival, local control, and progression-free survival 
rates were 58% (95% confidence interval [CI]: 46%–70%; 
T2a: 53%; T2b: 67%), 75% (95% CI: 63%–86%; T2a: 70%; 
T2b: 84%), and 46% (95% CI: 33%–59%; T2a: 43%; T2b: 
52%), respectively (Fig. 2). The projected 5-year rates were 
48%, 64%, and 36%, respectively. Local recurrence occurred 
in 19 patients (T2a: 13; T2b: 6); four patients with T2a disease 
and five patients with T2b developed local recurrence after 
2 years. Eleven patients (9 with T2a and 2 with T2b disease) 
developed hilar and/or mediastinal lymph node metastases, 
and two of them also had lung metastases. The rate for devel-
oping regional lymph node recurrence was 15% at 3 years and 
17% at 4 years. In addition, another 12 patients developed dis-
tant metastases. There were no significant differences accord-
ing to the T stage. There were no isolated nodal failures in the 
10 patients with a central legion.
TABLE 2.  Treatment Characteristics and Dose-Volume Analyses
Characteristics T2aN0M0 T2bN0M0 Total
No. of patients 47 23 70
Proton dose (GyE/Fr)
 80 /20 10  4 14
 60 /10 15  5 20
 66 /10  5  3  8
 70.2 /26  0  1  1
Carbon dose (GyE/Fr)
 52.8/4 11  5 16
 66 /10  4  4  8
 68.4 /9  2  1  3
Number of portals 1 / 2 / 3 / 4 11 / 24 / 11 / 1 3 / 14 / 5 / 1 14 / 38 / 16 / 2
 PTV volume (cm3)a 93.4 (43.0–178.3) 178.7 (81.1–315.2) 105.0 (43.0–315.2)
 PTV coverage (%) 88.0 (36.0-98.0) 92.0 (38.0–99.0) 91.0 (36.0–99.0)
 V20 Lungb (%)a 9.8 (4.9–21.0) 11.2 (5.0–24.1) 9.8 (4.9–24.1)
 V5 Lungb (%)a 13.9 (6.1–27.8) 14.3 (8.1–33.0) 14.0 (6.1–33.0)
a Median (range).
b Percentage of lung volume receiving 20 (5) GyE or a higher dose.
GyE, Gray equivalent; Fr, fractions; PTV, planning target volume.
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Figure 3 shows overall survival, local control, and pro-
gression-free survival rates according to medical operability 
for all patients. Operable patients had better survival rates 
than medically inoperable patients (p = 0.018), although local 
control and progression-free survival did not differ signifi-
cantly. For the 30 operable patients treated with PT or CIT, 
the 4-year overall survival, local control, and progression-
free survival rates were 72%, 73%, and 46%, respectively. 
The projected 5-year rates were 67%, 68%, and 40%, respec-
tively. Figure 4 shows overall survival, local control, and 
progression-free survival curves according to the beam type. 
There were no significant differences between PT and CIT. 
Figure 5 shows the curves according to histology. There were 
significant differences in the overall survival between adeno-
carcinoma and squamous cell carcinoma (p = 0.045), but the 
local control rates did not differ significantly between the two 
subtypes (p = 0.24).
Complications
Table 3 summarizes adverse events according to T 
stage. Severe RP (grade 3 or higher) was noted in two patients 
(3%) receiving CIT (both with T2b disease), with idiopathic 
pulmonary fibrosis and very poor respiratory function. 
They received steroid pulse therapy, and continuous oxygen 
inhalation became necessary. Most symptomatic grade 2 or 3 
RP occurred within 3 to 6 months after the start of irradiation. 
Severe dermatitis was noted in five patients (7%) (3 with T2a 
and 2 with T2b disease). For grade 3 and 4 dermatitis, wound 
care for skin ulcers (debridement, wound bed preparation, and 
moist wound healing, etc.) was required. In addition, they also 
received a few courses of hyperbaric oxygen therapy. The other 
main toxicities observed were a grade 2 rib fracture without 
the presence of cancer in 19 patients (27%) (13 with T2a, 6 
with T2b disease) and grade 2 fibrosis of the thoracic wall soft 
tissue in five patients (7%; 3 with T2a, 2 with T2b disease). 
Most of grade 2 rib fractures developed in patients treated 
before 2006 (12 with T2a and 4 with T2b disease). Most 
of these toxicities were late toxicities seen after 6 months. 
Among the 10 patients with a central lesion, there was only 
one patient with rib fracture, none with severe dermatitis, and 
one patient with grade 2 RP. Although pneumothorax related 
to particle therapy arose in two patients at 7 and 35 months, 
respectively, it was resolved after conservative treatment.
DISCUSSION
Although clinical trials of dose escalation in SBRT 
for T2 patients are in progress, surgical resection remains 
the standard procedure of treatment for T2a or T2bN0M0 
NSCLC patients. However, NSCLC patients over 70 years 
of age account for approximately one third of all patients 
at the time of diagnosis. Significant comorbid illness can 
also make them unfit for definitive surgery. Curative radia-
tion therapy has emerged as a promising therapeutic option. 
Previous reports have shown the efficacy and safety of SBRT 
and particle therapy in stage I NSCLC patients.8–11,17–22 For 
T2 patients, however, sufficiently high local control rates 
were not obtained.10,11,20–22 Table 4 summarizes the results of 
SBRT and particle therapy for T2 NSCLC from other institu-
tions.10,11,20–22 Although dermatitis and rib fracture were fre-
quently seen compared with SBRT, in the present study, PT 
and CIT were well tolerated and effective for T2a/bN0M0 
NSCLC. Especially, T2b tumors larger than 5 cm in diameter 
not indicated for SBRT using photons could be successfully 
treated using PT or CIT with relatively low pulmonary toxic-
ity compared with SBRT studies.22,23 For inoperable patients, 
FIGURE 1.  Example of particle ther-
apy planning for T2a non–small-cell 
carcinoma. A, Proton therapy with 
one portal; (B), carbon-ion therapy 
with one portal; (C), proton therapy 
with coplanar two portals; and (D), 
carbon-ion therapy with coplanar 
two portals.
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pulmonary toxicity was considered to be modest in both PT 
and CIT compared with other studies. As an advantage, PT 
and CIT can be delivered at a higher dose to the primary 
tumor, leading to improved local tumor control while simulta-
neously reducing the irradiated volume and doses delivered to 
the surrounding critical organs, regardless of the tumor size.24 
In our previous study, the local control rates were higher for 
adenocarcinoma than for squamous cell carcinoma,13 contrary 
to experience with photons, suggesting similar radiosensitiv-
ity of the two histological subtypes.25 However, there were no 
significant differences according to histology in the present 
study. The discrepancy may be because of improvement in 
planning and revision of the protocol. Further investigation 
about the differences according to the histology is warranted.
 In this study, T2b patients tended to do better than 
T2a patients, although overall survival, local control, and 
progression-free survival did not differ significantly between 
T2a and T2b patients. This was considered to be because of 
the small patient number. Generally, selection biases may 
exist for patients undergoing particle therapy compared with 
those undergoing photon SBRT, and further analysis of the 
influences of selection biases may be necessary. An important 
outcome of our results may be that particle therapy can be 
effective against large tumors more than 5 cm in diameter. A 
high local control rate is also reported for large hepatocellular 
carcinomas treated by PT.3
In the present study, regional lymph node metastases 
were frequently observed. The rates were relatively high com-
pared with those in some SBRT studies.17,18 Possibly, occult 
lymph node metastases, not detected by diagnostic imaging, 
would increase in proportion to tumor size. In addition, it 
might also be related to the dose distribution of particle ther-
apy with sharp dose fall-off and negligible incidental irradia-
tion or none to the mediastinum. Moreover, we usually use 
positron emission tomography-CT to determine the clinical 
stage, but do not use endobronchial ultrasonography. This 
FIGURE 2. A, Overall survival; (B), local control; 
and (C), progression-free survival curves after parti-
cle therapy for all (● ), T2a (○), and T2b (∆) patients. 
A, p = 0.65; (B), p = 0.75; and (C), p = 0.82.
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might underestimate the incidence of lymph node metasta-
sis at diagnosis. Further studies with more patients and more 
detailed analyses seem necessary.
In the present study, rib fracture and dermatitis (grade 
> 2) were also frequently seen, especially in patients treated 
between April 2003 and December 2006. During the early 
period, patients had been treated with only one portal to obtain 
enough SOBP.13 These data are similar to the results of Japanese 
photon SBRT studies.26,27 The low obesity rate in Japan might 
be associated with the high frequency of rib fracture. The skin 
and ribs are organs at risk in particle radiotherapy because of 
slightly higher entry doses regarding SOBP. In contrast, there 
were few adverse events for the patients with a central legion. 
These may be partly because chest-wall doses decrease with 
the increasing distance from the chest wall and unnecessary 
irradiation of the mediastinum can be minimized with particle 
radiotherapy. The previous protocol, 52.8 GyE delivered in 
four fractions, was stopped in January 2009. Since then, both 
PT and CIT protocols, 66 GyE delivered in 10 fractions, have 
been used. As for CIT, there may be no advantage to increasing 
fraction numbers in view of the low oxygen enhancement 
ratio.28 However, the oxygen enhancement ratio of PT remains 
unclear, so we plan to conduct in vitro and in vivo studies on 
the issue in the future. In addition, treatment planning for the 
layer-stacking beam method and scanning method should also 
be studied in the future to reduce the dose to the skin and ribs, 
taking late toxicities into consideration.29,30
The new TNM classification may imply a potential 
change in adjuvant treatment indications because of stage 
migration. This change is especially relevant in patients with 
T2bN0M0 tumors, upstaged from stage IB to stage IIA. 
Patients with stage II NSCLC according to the 6th TNM 
classification are known to benefit from adjuvant chemo-
therapy after surgery.31,32 It, therefore, seems reasonable to 
consider adjuvant chemotherapy or mediastinal radiation for 
T2bN0M0 patients. Several studies have investigated the effi-
cacy of salvage RT after surgery.33 Patients with hilar or medi-
astinal lymph node recurrence, who are not candidates for 
FIGURE 3. A, Overall survival; (B), local control; 
(C), and progression-free survival curves after 
particle therapy for operable (○) and inoperable (● ) 
patients. A, p = 0.018; (B), p = 0.54; (C), p = 0.82.
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chemotherapy, should be treated with radiation. As for medi-
astinal radiation after curative radiation to the primary lesion, 
to the best of knowledge, there is only one report regarding 
patients after SBRT.34 In that study, conventional radiotherapy 
could successfully salvage lymph node relapses after SBRT in 
a proportion of patients, after surgery, and seemed reasonably 
well tolerated. PT and CIT can reduce pulmonary toxicity by 
reducing the mean lung dose and low dose regions compared 
with SBRT.14,35,36 Moreover, PT and CIT stop just short of the 
mediastinum with the sharp distal fall-off of the Bragg peaks. 
Therefore, radiation for lymph node metastases after particle 
therapy may be safer than that after SBRT using photons. 
This could be a justification for further promotion of particle 
therapy for early-stage NSCLC. However, some patients are 
unfit for chemotherapy or mediastinal irradiation, so we will 
consider these adjuvant treatments for patients who can toler-
ate them.
Comparison of PT and CIT shows that low-dose regions 
spread into the surrounding normal lungs in PT because of 
the relatively large penumbra.37,38 Although CIT is superior 
in a simple dose-volume histogram comparison under the 
same conditions, the air gap is currently made as small as 
possible because of the collision detection system. Moreover, 
the beam directions are limited to three fixed positions in CIT. 
With CIT, tumors located in the posterior thorax have to be 
treated in a prone position. We use a respiratory gating sys-
tem, but the respiration curve is not stable in the prone posi-
tion. Therefore, internal margins need to be added despite 
the use of a respiratory gating system. However, PT can use 
a rotational gantry and patients can be treated in the supine 
position. The high positioning accuracy and stable respira-
tion curve in the supine position result in an advantage for 
PT in terms of dose-volume histograms. Moreover, we can 
also reduce the doses adjacent to organs at risk, especially to 
FIGURE 4. A, Overall survival; (B), local control, 
and (C), progression-free survival curves for patients 
receiving (● ) or (○). A, p = 0.80; (B), p = 0.85; and 
(C), p = 0.44. PT, proton therapy; CIT, carbon-ion 
therapy.
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the esophagus and vessels, using a rotational gantry. We plan 
to install an automatic bone verification system in the near 
future. This would serve to better increase precision with ste-
reotactic PT and CIT in combination with the respiratory gat-
ing system. Although there were no significant differences in 
the treatment results between PT and CIT in our previous and 
present studies,13 these studies were not randomized, and the 
biological effectiveness of the dose-fractionation schedules 
used may not necessarily be comparable. In the near future, 
we plan to conduct a randomized controlled trial of PT versus 
CIT for stage I NSCLC.
In conclusion, particle therapy is well tolerated and 
effective for T2a/bN0M0 NSCLC. Especially, T2b tumors 
not indicated for SBRT might be a good indication of par-
ticle therapy. In patients with large tumors, however, regional 
lymph node metastases developed frequently. It therefore 
seems worthwhile to consider chemotherapy or mediastinal 
irradiation as adjuvant therapy whenever possible. Also, ran-
domized studies comparing particle therapy and photon SBRT 
TABLE 3.  Complications Related to Particle Therapy
Adverse Event T2aN0M0 T2bN0M0 Total
No. of patients 47 23 70
Radiation pneumonitis
 Grade 2 / 3 7 / 0 3 / 2  3%a
Dermatitis
 Grade 2 / 3 / 4  7%a
 All patients 7 / 3 / 0 3 / 1 / 1  6%b
 Before 2006: T2a, 27; T2b, 9 6 / 2 / 0 2 / 0 / 0
Rib fracture grade 2
 All patients 13 6 27%
 Before 2006: T2a, 27; T2b, 9 12 4 44%b
Soft-tissue fibrosis grade 2  3 2  6%
The toxicities were evaluated according to the Common Terminology Criteria for 
Adverse Events version 4.0.
a Data are a percentage of grade 3 or more.
b Before 2006, most patients were treated with 1 or 2 portals.
FIGURE 5. A, Overall survival; (B), local control; 
(C), and progression-free survival curves for patients 
with adenocarcinoma (● ) and with squamous cell 
carcinoma SCC (○). A, p = 0.045; (B) , p = 0.24; (C), 
p = 0.54.
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are desirable. Further investigation of particle therapy is war-
ranted to define its role in T2a and T2bN0M0 NSCLC.
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